Irritable Bowel Syndrome (IBS) Treatment Market Growth Trajectory Through 2024-2033

Spread the love

The Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Irritable Bowel Syndrome (IBS) Treatment Market:

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

According to The Business Research Company’s Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024, The irritable bowel syndrome (ibs) treatment market size has grown rapidly in recent years. It will grow from $2.5 billion in 2023 to $2.77 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing prevalence of ibs, growing patient awareness, stress and lifestyle factors, patient advocacy and support groups, healthcare reimbursement policies.

The irritable bowel syndrome (ibs) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.29 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to patient-centric healthcare models, microbial therapies, blockchain in healthcare, patient-reported outcomes (pros), regulatory fast-track programs, health data interoperability. Major trends in the forecast period include integration of digital health solutions, advancements in diagnostic technologies, increased research and development investments, collaborations and partnerships, emergence of non-pharmacological therapies.

The rise in the prevalence of irritable bowel syndrome (IBS) is expected to propel the growth of the irritable bowel syndrome treatment market going forward. IBS is a chronic gastrointestinal disorder affecting the large intestine (colon). The rise in irritable bowel syndrome (IBS) prevalence is driven by poor lifestyles, bad eating habits, exposure to pollution, and increased stress levels. IBS treatment helps to reduce the severity and frequency of IBS symptoms, improve the quality of life, and enable individuals to manage their conditions better. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD), a US-based non-profit education and research organization, about 5–10% of the global population are having IBS in 2023 and between 25 and 45 million people in the United States are affected by IBS. Therefore, the rise in the prevalence of irritable bowel syndrome (IBS) is driving the growth of the IBS treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

The irritable bowel syndrome (ibs) treatment market covered in this report is segmented –

1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs

2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

4) By End-Users: Hospitals, Clinics, Homecare Settings

Product innovations have emerged as a key trend gaining popularity in the irritable bowel syndrome (IBS) market. Major irritable bowel syndrome (IBS) market players are concentrating their efforts on creating new and innovative, advanced products to strengthen their position in the market. For instance, in April 2022, Ardelyx, a US-based biotechnology company, launched IBSRELA, a first-in-class treatment for IBS-C in adults. It is the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C). IBSRELA, the first Ardelyx medicine to receive FDA approval, is the first novel mechanism therapy for IBS-C (irritable bowel syndrome-constipation) to be developed in almost ten years, and it provides a significant new treatment option for constipation, bloating, and stomach pain that are symptoms of this crippling disorder.

The irritable bowel syndrome (ibs) treatment market report table of contents includes:

Executive Summary
Irritable Bowel Syndrome (IBS) Treatment Market Characteristics
Irritable Bowel Syndrome (IBS) Treatment Market Trends And Strategies
Irritable Bowel Syndrome (IBS) Treatment Market – Macro Economic Scenario
Global Irritable Bowel Syndrome (IBS) Treatment Market Size and Growth

Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Benchmarking
Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Dashboard
Key Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market
Irritable Bowel Syndrome (IBS) Treatment Market Future Outlook and Potential Analysis
Appendix

Top Major Players: